InvestorsHub Logo
Followers 24
Posts 3015
Boards Moderated 0
Alias Born 01/18/2009

Re: None

Wednesday, 11/03/2010 2:06:52 AM

Wednesday, November 03, 2010 2:06:52 AM

Post# of 568
NewCardio to Conduct Corporate Update Conference Call on November 15, 2010

Date : 10/29/2010 @ 8:00AM
Source : PR Newswire
Stock : Newcardio (BB) (NWCI)

http://ih.advfn.com/p.php?pid=nmona&article=44991460

NewCardio, Inc. (OTC Bulletin Board: NWCI), a cardiovascular diagnostic solutions developer, announced today that the Company expects to file its Form 10-Q for the third quarter ended September 30, 2010 on November 15, 2010 and management will conduct a conference call to provide a corporate update and discuss progress as follows:

What: NewCardio Corporate Update Conference Call

When: 1:30 p.m. PT/ 4:30 p.m. ET, Monday, November 15, 2010

Where: Please dial 1-888-846-5003 (domestic) or 1-480-629-9856 (International) five to 10 minutes before the call. Investors will also have the opportunity to listen to the conference call and the replay on the News and Events section of the NewCardio website at: http://www.newcardio.com.

Questions: Select questions for the conference call will also be taken via email at nwci@haydenir.com and can be sent any time prior to the conference call's starting time.

Replay: A replay of the call will be available by dialing 1-877-870-5176 (domestic) or 1-858-384-5517 (international) and referencing passcode 4381453.

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12L ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

Investor Contact:


Hayden IR


Jeff Stanlis, Partner


(602) 476-1821


jeff@haydenir.com


SOURCE NewCardio, Inc.





posts are IMHO // either news - with LINK